Image Quality Assessment for Screening and Diagnostic Mammography
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02786004 |
|
Recruitment Status :
Completed
First Posted : May 30, 2016
Results First Posted : July 21, 2017
Last Update Posted : November 7, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Breast Health | Device: Full Field Digital Mammography Device: Digital Breast Tomosynthesis | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 24 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Diagnostic |
| Official Title: | Mammography Image Quality Assessment Reading NextGen Images for Screening and Diagnostic Use (MAGNIFI) |
| Study Start Date : | February 2016 |
| Actual Primary Completion Date : | May 2016 |
| Actual Study Completion Date : | May 2016 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Full Field Digital Mammography
2-dimensional breast imaging
|
Device: Full Field Digital Mammography
Other Name: 2D Mammography |
|
Experimental: Digital Breast Tomosynthesis
3-dimensional breast imaging
|
Device: Digital Breast Tomosynthesis
Other Name: DBT |
- Number of Participants With Acceptable Overall Clinical Image Quality [ Time Frame: At enrollment completion approximately 3 months post initiation ]Overall clinical image quality was assessed by Mammography Quality Standards Act (MQSA) qualified radiologists ("readers"). Readers documented acceptability of FFDM and DBT image quality and image characteristics, as set for in the Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Full Field Digital Mammography System (2012).
- Number of Subjects Experiencing a Device Related Adverse Events, Serious Adverse Event, Unanticipated Device Effect, and Device Defects by Overall Occurrence. [ Time Frame: Through study completion, approximately 3 months ]Safety-related endpoint data (adverse events, serious adverse event, unanticipated device effect, and device defects) were monitored from all subjects for the duration of their participation. Results were summarized by cohort.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 40 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Are women aged 40 years or older (≥40 years old);
- Have had a FFDM (Full Field Digital Mammography) or DBT (Digital Breast Tomosynthesis) breast imaging exam within 30 days prior to enrollment;
- Have breast sizes compatible with the dimensions of a 24x29 cm image detector without anatomical cut-off;
- Are able to walk without assistive devices;
- Are sterile; post-menopausal; or if of childbearing potential, have a negative pregnancy test or is willing to provide urine sample to confirm no pregnancy, within 30 days of imaging exam; and
- Are willing to provide written informed consent to participate.
Exclusion Criteria:
- Have been previously included in this study or are participating in another trial expected to interfere with study procedures or outcomes;
- Have a history of breast biopsy, lumpectomy or mastectomy, or reconstruction on either breast;
- Are currently lactating;
- Are currently undergoing radiotherapy or chemotherapy , or have a history of prior radiotherapy treatment on either breast; or
- If enrolled to the DBT (Digital Breast Tomosynthesis) cohort, have breast implants (breast implants are not exclusionary in the FFDM (Full Field Digital Mammography) cohort).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02786004
| United States, North Carolina | |
| Carolina Breast Imaging Specialist | |
| Greenville, North Carolina, United States, 27834 | |
| Principal Investigator: | Bruce Schroeder, MD | Carolina Breast Imaging Specialists |
| Responsible Party: | GE Healthcare |
| ClinicalTrials.gov Identifier: | NCT02786004 |
| Other Study ID Numbers: |
124.03-2015-GES-0004 |
| First Posted: | May 30, 2016 Key Record Dates |
| Results First Posted: | July 21, 2017 |
| Last Update Posted: | November 7, 2018 |
| Last Verified: | October 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |

